Metrics Inc. now offers microbiology-testing services to the contract pharmaceutical industry
METRICS NOW OFFERS MICROBIOLOGY TESTING
New microbiology services part of $18-million facility expansion doubling Metrics' size
GREENVILLE, N.C.- Metrics Inc. now offers microbiology-testing services to the contract pharmaceutical industry.
The new services stem from the company's recent $18-million, 47,000-square-foot expansion that doubled its facility size and dramatically grew the company’s service capabilities to clients.
Metrics Inc., headquartered in Greenville, N.C., is one of the fastest-growing contract pharmaceutical development laboratories in the United States. Metrics provides quality pharmaceutical formulation, clinical trial material (Phase I, II and III) and commercial manufacturing, and analytical development/validation services to the pharmaceutical industry.
"Offering our clients all the services they need under one roof has been a long-time goal for us," said Phil Hodges, president. "We're glad we can add value to the relationships we've developed with our clients, and know these services will make Metrics even more competitive when it comes to attracting new clients."
As part of its new microbiology laboratory, Metrics has brought antibiotic assay and sterility testing online, enhancing its ability to offer full microbiological support of sterile products. The company routinely performs bacterial endotoxin and particulate matter testing on parenterals.
Metrics' facility addition also includes four new fully operational analytical laboratories, validated and ready to handle projects; stability storage with state-of-the-art environmental specialties chambers complete with redundant mechanical systems and strictly limited personnel access; and a dedicated cytotoxic and potent compound laboratory.
For more information about Metrics, visit www.metricsinc.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.